PALVELLA THERAPEUTICS, INC.
PVLANasdaq
$157.24
↑ +6.4%Jul 17 close · end-of-day
Price
1Y↑ +453.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.1B
Enterprise Value
$1.8B
P/E
—
P/S
—
P/B
8.9
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$49.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-21.2%
ROIC
—
Debt / Equity
—
Net Cash
$261.9M
Return 1Y
+403.5%
Company profile
Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases. Palvella Therapeutics is headquartered in Wayne, Pennsylvania.
- CEO
- Wes Kaupinen
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Pennsylvania
- Website
- palvellatx.com
Earnings
PVLA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.20↑ +62.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $29.3M | $31.4M | $25.9M | $42.8M | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$33.9M | -$51.8M | -$43.5M | -$11.9M | -$14.1M | -$38.6M |
| Net income | -$37.2M | -$45.7M | -$33.3M | $18.7M | -$17.4M | -$41.7M |
| Diluted EPS | -$0.68 | -$0.71 | — | $2.17 | -$7.83 | -$3.71 |
| Operating cash flow | -$45.9M | -$7.7M | -$59.9M | -$13.7M | -$10.8M | -$25.0M |
| Free cash flow | -$48.6M | -$8.6M | -$61.0M | -$13.9M | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -115.7% | -165.0% | -167.8% | -27.7% | — | — |
| Net margin | -127.0% | -145.6% | -128.5% | 43.7% | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.9M | -$5.1M | -$4.4M | -$7.9M | -$9.3M | -$10.2M | -$11.3M | -$14.9M |
| Net income | -$4.2M | -$6.8M | -$4.0M | -$8.2M | -$9.5M | -$11.3M | -$12.7M | -$15.8M |
| Diluted EPS | -$2.47 | -$3.94 | $0.12 | -$0.74 | -$0.86 | -$1.03 | -$1.08 | -$1.20 |
| Operating cash flow | -$1.6M | -$2.7M | -$5.4M | -$6.8M | -$5.4M | -$7.9M | -$4.9M | -$10.9M |
| Free cash flow | -$1.6M | -$2.7M | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 15, 2026
Jun 27, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.